Edwards Lifesciences Corp reports $1.72 billion revenue for quarter ended September 30, 2026, up 10.5%
Edwards Lifesciences Corp reported revenue of $1.72 billion for the quarter ended September 30, 2026, an increase of 10.5% from the same quarter a year earlier ($1.55 billion).
For the same period it posted net income of $307.5 million, up 5.6%, or $0.53 per diluted share (0.50 a year earlier).
That is a net margin of 17.9%.
On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).
Is Edwards Lifesciences Corp halal?
See the full AAOIFI screening of Edwards Lifesciences Corp
See the full AAOIFI screening of Edwards Lifesciences Corp
Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.